DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHEN Xi, CHU Yu- Waye, LI Chi- Chung, TO Iris, Tranthuyngan, O''HEAR Carol, Elaine, WEI Michael, C, BENDER Brendan, Christian, HRISTOPOULOS Maria, SIMKO III Stephen, James, TOTPAL Klara, WANG Hong, YIN Shen
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate. La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no Hodgkin). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo celular positivo para CD20 (por ejemplo, trastorno proliferativo de linfocitos B) mediante la administración de una combinación de un anticuerpo biespecífico anti-CD20/anti-CD3 y un conjugado anticuerpo fármaco anti-CD79b.